Open-Label Extension Study of Kuvan for Autism

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00943579

Condition

Autistic Disorder

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This is an open-label extension study available only to subjects who completed an earlier double-blind, placebo-controlled study of sapropterin in children with autism.

Eligibility Criteria

Birth Sex

All

Age

3 Years to 6 Years

Healthy Volunteers

No

Drug/Treatment:

Kuvan®

Phase:

Phase 2/Phase 3

Study Type:

Interventional

Number of Participants:

41

Study Started:

2009-08

Study Updated:

2018-05-02

Trial Locations

  • The Children's Health Council

    Palo Alto, California, United States

Inclusion Criteria

  • All subjects must have completed earlier trial, CHC 0901 (NCT00850070)
  • Parents must be willing and able to sign informed consent

Exclusion Criteria

  • Child failed to complete CHC 0901 (NCT00850070

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form